World Journal of Urology,
Год журнала:
2021,
Номер
39(9), С. 3337 - 3344
Опубликована: Март 13, 2021
Abstract
Purpose
To
investigate
the
association
of
patients’
sex
with
recurrence
and
disease
progression
in
patients
treated
intravesical
bacillus
Calmette–Guérin
(BCG)
for
T1G3/HG
urinary
bladder
cancer
(UBC).
Materials
methods
We
analyzed
data
2635
adjuvant
BCG
T1
UBC
between
1984
2019.
accounted
missing
using
multiple
imputations
adjusted
covariate
imbalance
males
females
inverse
probability
weighting
(IPW).
Crude
IPW-adjusted
Cox
regression
analyses
were
used
to
estimate
hazard
ratios
(HR)
their
95%
confidence
intervals
(CI)
HG-recurrence
progression.
Results
A
total
2170
(82%)
465
(18%)
available
analysis.
Overall,
1090
(50%)
244
(52%)
experienced
recurrence,
391
104
(22%)
On
analyses,
female
was
associated
(HR
1.25,
95%CI
1.01–1.56,
p
=
0.04)
but
not
1.06,
0.92–1.22,
0.41).
1056
adequate
BCG.
In
these
patients,
on
0.99,
0.80–1.24,
0.96),
1.00,
0.78–1.29,
0.99)
or
1.12,
0.78–1.60,
0.55).
Conclusion
Our
analysis
generates
hypothesis
a
differential
response
if
adequately
treated.
Further
studies
should
focus
sex-based
differences
innate
adaptive
immune
system
response.
Biology of Sex Differences,
Год журнала:
2022,
Номер
13(1)
Опубликована: Май 3, 2022
Abstract
Sex
and
age
associated
differences
in
the
tumor
immune
microenvironment
of
non-muscle
invasive
bladder
(NMIBC)
cancer
clinical
outcomes
are
emerging
indicators
treatment
outcomes.
The
incidence
urothelial
carcinoma
is
four
times
higher
males
than
females;
however,
females
tend
to
present
with
a
more
aggressive
disease,
poorer
response
immunotherapy
suffer
worse
Recent
findings
have
demonstrated
sex
muscle
However,
significant
gap
knowledge
remains
respect
current
pre-clinical
modeling
approaches
precisely
recapitulate
these
towards
improved
therapeutic
design.
Given
similarities
mucosal
physiology
between
humans
mice,
we
evaluated
age-related
alterations
healthy
murine
bladders.
Bulk-RNA
sequencing
multiplex
immunofluorescence-based
spatial
profiling
bladders
from
male
female
mice
groups
spanning
young
old
showed
highly
altered
landscape
that
exhibited
differences,
particularly
context
B
cell
mediated
responses.
Spatial
bladders,
using
markers
specific
macrophages,
T
cells,
activated
dendritic
high
endothelial
venules,
myeloid
cells
PD-L1
checkpoint
differences.
Bladders
older
also
presence
tertiary
lymphoid
structures
(TLSs)
compared
both
equivalents.
N
-butyl-
-(4-hydroxybutyl)
nitrosamine
(BBN)
carcinogen
exposed
revealed
similar
frequency
TLS
formation,
and,
latency
induction.
These
support
incorporation
as
factors
will
potentially
advance
field
immunotherapeutic
drug
development
improve
World Journal of Urology,
Год журнала:
2023,
Номер
41(7), С. 1763 - 1774
Опубликована: Май 20, 2023
Abstract
Purpose
To
analyze
and
summarize
the
efficacy
of
immune
checkpoint
inhibitor
(ICI)
alone
or
in
combination
therapy
for
renal
cell
carcinoma
(RCC)
urothelial
(UC)
stratified
by
sex.
Methods
Three
databases
were
queried
October
2022
randomized
controlled
trials
(RCTs)
analyzing
RCC
UC
patients
treated
with
ICIs.
We
analyzed
association
between
sex
ICIs
across
several
clinical
settings.
The
outcomes
interest
overall
survival
(OS)
progression-free
metastatic
setting
disease-free
(DFS)
adjuvant
setting.
Results
Overall,
16
RCTs
included
meta-analyses
network
meta-analyses.
In
first-line
treatment
(mRCC)
(mUC)
patients,
ICI-based
therapies
significantly
improved
OS
compared
to
current
standard
care,
regardless
Adjuvant
ICI
monotherapy
reduced
risk
disease
recurrence
female
locally
advanced
(pooled
hazard
ratio
[HR]:
0.71,
95%
confidence
interval
[CI]
0.55–0.93)
but
not
male
and,
conversely,
muscle-invasive
HR:
0.80,
95%CI
0.68–0.94)
patients.
Treatment
ranking
analyses
mRCC
mUC
showed
different
results
sexes.
Of
note,
regarding
RCC,
pembrolizumab
(99%)
had
highest
likelihood
DFS
males,
whereas
atezolizumab
(84%)
females.
Conclusions
benefit
was
seen
Sex-based
recommendations
regimens
according
may
help
guide
decision-making.
Frontiers in Oncology,
Год журнала:
2025,
Номер
15
Опубликована: Фев. 14, 2025
Purpose
Bladder
cancer
is
a
public
health
concern,
with
smoking
and
occupational
exposure
being
major
risk
factors.
However,
specific
risks
in
women,
particularly
hormonal,
lifestyle,
environmental
factors,
are
underexplored.
This
study
aimed
to
assess
these
factors
focusing
on
smoking,
exposure,
recurrent
urinary
tract
infections
(UTIs),
body
mass
index
(BMI),
menopausal
status,
family
history
of
cancer.
Materials
methods
retrospective
cohort
included
850
women
diagnosed
bladder
(2018–2023)
age-matched
controls.
Data
UTIs,
BMI,
were
collected
from
medical
records:
multivariate
logistic
regression
propensity
score
matching
identified
independent
Subgroup
analysis
explored
interactions
between
status
other
Results
Smoking
(OR
=
2.15,
p
0.002),
1.89,
0.007),
UTIs
1.72,
0.013)
significant
post-menopausal
women.
Menopausal
amplified
the
effects
but
was
not
an
predictor.
BMI
showed
no
associations.
Conclusion
Smoking,
key
for
especially
highlighting
need
targeted
prevention
strategies.
Cancers,
Год журнала:
2023,
Номер
15(3), С. 566 - 566
Опубликована: Янв. 17, 2023
Cisplatin-based
neoadjuvant
chemotherapy
followed
by
radical
cystectomy
is
the
current
standard
of
care
for
muscle-invasive
bladder
cancer
(MIBC).
However,
less
than
half
patients
are
candidates
this
treatment,
and
50%
will
develop
metastatic
disease.
Adjuvant
could
be
offered
if
treatment
has
not
been
administered
suitable
patients.
It
important
to
reduce
risk
systemic
recurrence
improve
prognosis
localized
MIBC.
Systemic
therapy
urothelial
carcinoma
evolved
in
recent
years.
Immune
checkpoint
inhibitors
targeted
agents,
such
as
antibody-drug
conjugates
or
FGFR
inhibitors,
new
therapeutic
alternatives
have
shown
their
benefit
advanced
Currently,
several
clinical
trials
investigating
role
these
drugs,
monotherapy
combination
with
chemotherapy,
adjuvant
settings
promising
outcomes.
In
addition,
development
predictive
biomarkers
predict
responses
therapies.
Frontiers in Pharmacology,
Год журнала:
2025,
Номер
16
Опубликована: Янв. 29, 2025
Purpose
Numerous
prior
analyses
have
highlighted
a
potential
link
between
androgen
suppression
therapy
(AST)
and
bladder
cancer
(BCa).
However,
there
is
notable
gap
in
research
specifically
examining
the
influence
of
finasteride
on
BCa
risk
clinical
outcomes.
This
study
aimed
to
evaluate
preventive
therapeutic
value
for
patients.
Methods
meta-analysis
adhered
Preferred
Reporting
Items
Systematic
Reviews
Meta-Analyses
(PRISMA)
Guidelines.
The
PubMed,
Embase,
Cochrane
Library,
Web
Science
databases
were
searched
up
20
December
2024,
identify
studies
that
examined
intake
its
impact
incidence
prognosis
patients
with
BCa.
Data
was
extracted
further
analysis
by
two
different
reviewers
who
independently
titles
abstracts
included
articles.
Subgroup
leave-one-out
sensitivity
analyses,
applied
mitigate
confounding
factors
associated
heterogeneity.
Results
Our
investigation
revealed
markedly
decreased
likelihood
developing
(hazard
ratio
[HR]:
0.75,
95%
confidence
interval
[CI]:
0.63–0.88).
indicated
effect
generally
consistent,
regardless
region,
types
research.
Furthermore,
no
disparities
observed
OS,
CSS,
or
RFS
group
control
group.
Conclusion
Finasteride
plays
protective
role
against
progression
BCa,
nevertheless,
effects
prognostic
outcomes,
including
RFS,
remain
inconclusive.
Additional
multi-center
prospective
long-term
follow-up
are
required
validate
prophylactic
cancer.
review
registration
number
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=525046
,
identifier
CRD42024525046.
